RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Laboratory Corporation of America Holdings Stock

Laboratory Corporation of America Holdings Revenue 2024

Laboratory Corporation of America Holdings Revenue

13.35 B USD

Ticker

LH

ISIN

US50540R4092

WKN

895308

In 2024, Laboratory Corporation of America Holdings's sales reached 13.35 B USD, a 9.8% difference from the 12.16 B USD sales recorded in the previous year.

The Laboratory Corporation of America Holdings Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2028e14.223,69
2027e13.924,21
2026e14.7522,82
2025e14.1123,85
2024e13.3525,20
202312.1627,67
202211.8631,26
202113.1438,01
202013.9835,43
201911.5528,15
201811.3328,03
201710.3129,99
20169.5529,88
20158.6833,45
20146.0136,65
20135.8138,27
20125.6739,67
20115.5441,05
2010541,93
20094.6941,98
20084.5141,60
20074.0741,57
20063.5942,59
20053.3341,78
20043.0841,80

Laboratory Corporation of America Holdings Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Laboratory Corporation of America Holdings, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Laboratory Corporation of America Holdings from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Laboratory Corporation of America Holdings’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Laboratory Corporation of America Holdings. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Laboratory Corporation of America Holdings’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Laboratory Corporation of America Holdings’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Laboratory Corporation of America Holdings’s growth potential.

Laboratory Corporation of America Holdings Revenue, EBIT and net profit per share

DateLaboratory Corporation of America Holdings RevenueLaboratory Corporation of America Holdings EBITLaboratory Corporation of America Holdings Net Income
2028e14.2 B undefined2.39 B undefined1.65 B undefined
2027e13.9 B undefined2.26 B undefined1.59 B undefined
2026e14.75 B undefined2.13 B undefined1.52 B undefined
2025e14.11 B undefined1.97 B undefined1.37 B undefined
2024e13.35 B undefined1.84 B undefined1.27 B undefined
202312.16 B undefined1.12 B undefined418 M undefined
202211.86 B undefined1.75 B undefined1.28 B undefined
202113.14 B undefined3.07 B undefined2.38 B undefined
202013.98 B undefined3 B undefined1.56 B undefined
201911.55 B undefined1.49 B undefined823.8 M undefined
201811.33 B undefined1.37 B undefined883.7 M undefined
201710.31 B undefined1.38 B undefined1.23 B undefined
20169.55 B undefined1.33 B undefined711.8 M undefined
20158.68 B undefined1.11 B undefined437.6 M undefined
20146.01 B undefined922.1 M undefined511.2 M undefined
20135.81 B undefined1.01 B undefined574 M undefined
20125.67 B undefined1.05 B undefined583.1 M undefined
20115.54 B undefined1.03 B undefined520 M undefined
20105 B undefined991 M undefined558 M undefined
20094.69 B undefined949.4 M undefined543.3 M undefined
20084.51 B undefined881 M undefined465 M undefined
20074.07 B undefined827.6 M undefined476.8 M undefined
20063.59 B undefined698.1 M undefined431.6 M undefined
20053.33 B undefined635 M undefined386.2 M undefined
20043.08 B undefined597.5 M undefined363 M undefined

Laboratory Corporation of America Holdings stock margins

The Laboratory Corporation of America Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Laboratory Corporation of America Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Laboratory Corporation of America Holdings.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Laboratory Corporation of America Holdings's sales revenue. A higher gross margin percentage indicates that the Laboratory Corporation of America Holdings retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Laboratory Corporation of America Holdings's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Laboratory Corporation of America Holdings's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Laboratory Corporation of America Holdings's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Laboratory Corporation of America Holdings. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Laboratory Corporation of America Holdings's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Laboratory Corporation of America Holdings Margin History

Laboratory Corporation of America Holdings Gross marginLaboratory Corporation of America Holdings Profit marginLaboratory Corporation of America Holdings EBIT marginLaboratory Corporation of America Holdings Profit margin
2028e27.67 %16.83 %11.62 %
2027e27.67 %16.24 %11.47 %
2026e27.67 %14.43 %10.32 %
2025e27.67 %13.97 %9.73 %
2024e27.67 %13.77 %9.51 %
202327.67 %9.24 %3.44 %
202231.26 %14.77 %10.78 %
202138.01 %23.39 %18.1 %
202035.43 %21.48 %11.13 %
201928.15 %12.86 %7.13 %
201828.03 %12.12 %7.8 %
201729.99 %13.35 %11.9 %
201629.88 %13.91 %7.45 %
201533.45 %12.8 %5.04 %
201436.65 %15.34 %8.5 %
201338.27 %17.44 %9.88 %
201239.67 %18.49 %10.28 %
201141.05 %18.57 %9.38 %
201041.93 %19.8 %11.15 %
200941.98 %20.22 %11.57 %
200841.6 %19.56 %10.32 %
200741.57 %20.34 %11.72 %
200642.59 %19.44 %12.02 %
200541.78 %19.08 %11.61 %
200441.8 %19.37 %11.77 %

Laboratory Corporation of America Holdings Aktienanalyse

What does Laboratory Corporation of America Holdings do?

The Laboratory Corporation of America Holdings, also known as LabCorp, is an American company that has been operating in the medical diagnostics industry since 1978. It was founded by a doctor and a laboratory scientist with the goal of simplifying and improving the diagnostic process. LabCorp is now the largest independent diagnostic company in the world, with over 60,000 employees. LabCorp's business model is to contribute to the prevention, diagnosis, and treatment of diseases through its comprehensive diagnostic services. The company offers a wide range of medical laboratory tests, clinical studies, and DNA analysis services. LabCorp operates more than 2,000 locations in the United States, Canada, and Europe, and provides its services worldwide. LabCorp is divided into three business segments: Diagnostics, Drug Development, and CRO (contract research organization). Under the Diagnostics segment, the company offers laboratory tests for clinical detection, cancer diagnosis, genetic testing, and more. The company specializes in blood, body fluid, and tissue analyses and also offers a variety of specialized tests to answer specific medical questions. LabCorp's Drug Development segment aims to accelerate and improve drug development through its comprehensive clinical studies. The company assists with study coordination and compliance with regulatory requirements to ensure accurate and reliable study results. LabCorp's CRO segment offers clinical study services, including study planning, design, execution, and analysis. This enables the company to develop groundbreaking treatment options for diseases that do not yet have adequate therapies. LabCorp is also heavily involved in the development of personalized diagnostics to provide patients with even more accurate diagnosis and treatment options. LabCorp offers a wide range of products. The company is a leading provider of clinical laboratory services and offers a broad range of laboratory tests for infections, hormonal disorders, autoimmune diseases, allergies, and cancer. Some of the specialized tests offered by LabCorp include genetic testing for cancer diagnosis and inherited metabolic disorders. In the Drug Development segment, the company offers a wide range of clinical studies aimed at developing new drugs and therapies. LabCorp also utilizes its DNA identification services to confirm the identity of individuals or assist in forensic cases. In summary, LabCorp is a successful company specialized in medical diagnostics. Over the past 40 years, the company has experienced impressive growth and positioned itself as a leading provider of clinical laboratory services. With its wide range of diagnostic services, clinical studies, and DNA identification services, LabCorp provides innovative solutions for the medical challenges of the future. Laboratory Corporation of America Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Laboratory Corporation of America Holdings's Sales Figures

The sales figures of Laboratory Corporation of America Holdings originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Laboratory Corporation of America Holdings’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Laboratory Corporation of America Holdings's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Laboratory Corporation of America Holdings’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Laboratory Corporation of America Holdings stock

How much revenue did Laboratory Corporation of America Holdings generate this year?

Laboratory Corporation of America Holdings has achieved a revenue of 13.35 B USD this year.

How much was the turnover of the company Laboratory Corporation of America Holdings compared to the previous year?

The revenue of Laboratory Corporation of America Holdings has increased by 9.8% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Laboratory Corporation of America Holdings?

The revenue of Laboratory Corporation of America Holdings is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Laboratory Corporation of America Holdings measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Laboratory Corporation of America Holdings so important for investors?

The revenue of Laboratory Corporation of America Holdings is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Laboratory Corporation of America Holdings pay?

Over the past 12 months, Laboratory Corporation of America Holdings paid a dividend of 2.88 USD . This corresponds to a dividend yield of about 1.29 %. For the coming 12 months, Laboratory Corporation of America Holdings is expected to pay a dividend of 3.19 USD.

What is the dividend yield of Laboratory Corporation of America Holdings?

The current dividend yield of Laboratory Corporation of America Holdings is 1.29 %.

When does Laboratory Corporation of America Holdings pay dividends?

Laboratory Corporation of America Holdings pays a quarterly dividend. This is distributed in the months of March, June, June, September.

How secure is the dividend of Laboratory Corporation of America Holdings?

Laboratory Corporation of America Holdings paid dividends every year for the past 7 years.

What is the dividend of Laboratory Corporation of America Holdings?

For the upcoming 12 months, dividends amounting to 3.19 USD are expected. This corresponds to a dividend yield of 1.43 %.

In which sector is Laboratory Corporation of America Holdings located?

Laboratory Corporation of America Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Laboratory Corporation of America Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Laboratory Corporation of America Holdings from 9/13/2024 amounting to 0.72 USD, you needed to have the stock in your portfolio before the ex-date on 8/29/2024.

When did Laboratory Corporation of America Holdings pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Laboratory Corporation of America Holdings in the year 2023?

In the year 2023, Laboratory Corporation of America Holdings distributed 2.16 USD as dividends.

In which currency does Laboratory Corporation of America Holdings pay out the dividend?

The dividends of Laboratory Corporation of America Holdings are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Laboratory Corporation of America Holdings

Our stock analysis for Laboratory Corporation of America Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Laboratory Corporation of America Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.